Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

Condition:   T2DM Interventions:   Drug: CSII+Vildagliptin;   Drug: CSII(insulin Lispro) Sponsor:   The First Affiliated Hospital of Xiamen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials